Uterine Fibroids

Interim assessment of 1-month data from uterine fibroid therapy released

Published in Drug Week, January 28th, 2005

Zonagen, Inc. (ZNG) released preliminary 1 month findings from its study of Progenta in the treatment of uterine fibroids. The study included 3 dose levels of Progenta as well as placebo and positive control arms.

The positive control was Lucrin, a GnRH agonist, commonly used for the treatment of fibroids. Progenta was administered as a daily oral dose of either 12.5 mg, 25 mg, or 50 mg capsules.

After 1-month exposure, only the high dose of Progenta achieved a statistically significant reduction of fibroid size as compared to baseline. Patients on the highest dose of Progenta experienced a statistically significant reduction in fibroid size of 24.2%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-01-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry